Brokers Set Expectations for Zoetis' Q2 Earnings (NYSE:ZTS)

Zoetis Inc. (NYSE:ZTS - Free Report) - Equities research analysts at Leerink Partnrs raised their Q2 2025 earnings estimates for shares of Zoetis in a report issued on Thursday, July 17th. Leerink Partnrs analyst D. Clark now expects that the company will post earnings per share of $1.61 for the quarter, up from their prior estimate of $1.60. Leerink Partnrs currently has a "Hold" rating on the stock. The consensus estimate for Zoetis' current full-year earnings is $6.07 per share. Leerink Partnrs also issued estimates for Zoetis' FY2026 earnings at $6.81 EPS, FY2027 earnings at $7.26 EPS and FY2028 earnings at $7.73 EPS.

Other research analysts have also recently issued research reports about the stock. UBS Group dropped their target price on shares of Zoetis from $189.00 to $170.00 and set a "neutral" rating for the company in a report on Wednesday, May 7th. Piper Sandler raised their price objective on shares of Zoetis from $205.00 to $210.00 and gave the stock an "overweight" rating in a research report on Monday, May 12th. Stifel Nicolaus downgraded shares of Zoetis from a "buy" rating to a "hold" rating and reduced their price objective for the stock from $165.00 to $160.00 in a research report on Wednesday, June 18th. Finally, Leerink Partners cut Zoetis from an "outperform" rating to a "market perform" rating and cut their target price for the stock from $180.00 to $155.00 in a report on Thursday. Four investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Zoetis presently has an average rating of "Moderate Buy" and a consensus target price of $204.63.

Zoetis Stock Performance

Shares of NYSE:ZTS traded down $1.29 on Monday, hitting $147.31. The company had a trading volume of 2,996,578 shares, compared to its average volume of 2,624,290. Zoetis has a 1-year low of $139.70 and a 1-year high of $200.33. The stock has a market cap of $65.59 billion, a price-to-earnings ratio of 24.68, a P/E/G ratio of 2.46 and a beta of 0.91. The stock has a 50 day moving average price of $160.77 and a 200 day moving average price of $161.42. The company has a current ratio of 1.74, a quick ratio of 1.04 and a debt-to-equity ratio of 1.12.

Zoetis (NYSE:ZTS - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The company reported $1.48 earnings per share for the quarter, beating the consensus estimate of $1.40 by $0.08. Zoetis had a net margin of 27.12% and a return on equity of 55.48%. The firm had revenue of $2.22 billion during the quarter, compared to analysts' expectations of $2.20 billion. During the same quarter last year, the company posted $1.38 EPS. The company's quarterly revenue was up 1.4% compared to the same quarter last year.

Zoetis Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, September 3rd. Stockholders of record on Friday, July 18th will be issued a $0.50 dividend. This represents a $2.00 annualized dividend and a dividend yield of 1.36%. The ex-dividend date is Friday, July 18th. Zoetis's payout ratio is currently 35.91%.

Insider Buying and Selling at Zoetis

In related news, EVP Roxanne Lagano sold 652 shares of the firm's stock in a transaction that occurred on Tuesday, June 3rd. The stock was sold at an average price of $170.00, for a total value of $110,840.00. Following the completion of the transaction, the executive vice president directly owned 15,129 shares of the company's stock, valued at $2,571,930. This trade represents a 4.13% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 0.16% of the company's stock.

Hedge Funds Weigh In On Zoetis

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Schroder Investment Management Group increased its holdings in shares of Zoetis by 2.6% in the fourth quarter. Schroder Investment Management Group now owns 245,726 shares of the company's stock valued at $40,036,000 after buying an additional 6,169 shares in the last quarter. Vanguard Group Inc. raised its stake in Zoetis by 0.3% during the 4th quarter. Vanguard Group Inc. now owns 41,366,877 shares of the company's stock valued at $6,739,905,000 after purchasing an additional 120,158 shares during the period. Portside Wealth Group LLC grew its holdings in shares of Zoetis by 24.7% during the 1st quarter. Portside Wealth Group LLC now owns 33,709 shares of the company's stock valued at $5,550,000 after acquiring an additional 6,672 shares in the last quarter. Tandem Investment Advisors Inc. grew its holdings in shares of Zoetis by 100.3% during the 1st quarter. Tandem Investment Advisors Inc. now owns 395,626 shares of the company's stock valued at $65,140,000 after acquiring an additional 198,089 shares in the last quarter. Finally, Horizon Financial Services LLC purchased a new position in shares of Zoetis during the 1st quarter valued at $380,000. 92.80% of the stock is currently owned by institutional investors and hedge funds.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.